Current Epidemiological Data Can Help Predict Future Incidence of CCA

March 2023, Vol 4, No 1

Cholangiocarcinoma (CCA), a rare and aggressive form of cancer, has seen a steady increase in incidence in the United States, with a predominant increase in intrahepatic CCA (iCCA), from 2001 to 2017 based on a recent epidemiological study. Dr Sri Harsha Tella presented results from a retrospective study that aimed to evaluate the future incidence of CCA with subgroup stratification based on CCA subtype, age, sex, and race in the hope that epidemiological data may aid in prevention planning and treatment strategies.

Histologically confirmed patient cases of CCA from 2000 to 2017 were obtained from 18 of the National Cancer Institute’s Surveillance, Epidemiology, and End Results registries. Age-period-cohort models were applied to estimate future CCA incidence rates (per 100,000). Incidence forecast multiplied by corresponding US census population projections was used to estimate disease burden. A total of 12,737 patients with iCCA and 8395 with extrahepatic CCA (eCCA) were included in the final analysis. The overall observed age-adjusted incidence of iCCA from 2000 to 2017 was 1.07 and is predicted to rise by 99% to 2.13 by 2029, with predominant increases in patients aged 70 to 79 years and in White men and women. The incidence of eCCA is also expected to rise 36.5% compared with 2001 to 2017, from 0.74 to 1.01, by 2029, predominantly in Black and Hispanic patients. Notably, a stable and decreasing incidence rate was seen in White and Asian women.

Overall, it is expected that the incidence of iCCA and eCCA will rise over the coming years. These studies suggest the need for urgent preventive measures; however, further studies are needed to determine contributing factors to the increase in CCA incidence.

Source: Tella SH, Hodge DO, Wieczorek MA, et al. A glimpse into the future of cholangiocarcinoma: predicting the future incidence based on the current epidemiological data. Poster presented at: ASCO Gastrointestinal Cancers Symposium, January 19-21, 2023; San Francisco, CA. Abstract 616.

Related Items

Characterization of Long-Term Survivors in TOPAZ-1
March 2023, Vol 4, No 1
Researchers examined the characteristics, outcomes, and genomic profiles of patients with advanced biliary tract cancer who were treated with durvalumab plus gemcitabine/cisplatin and experienced long-term survival.
MDM2-p53 Antagonist BI 907828 Demonstrated Promising Activity in Patients with Advanced BTC
March 2023, Vol 4, No 1
The novel MDM2-p53 antagonist BI 907828 is being investigated as a first-line treatment in patients with advanced biliary tract cancer.
Treatment and Survival Outcomes with Systemic Therapy for Patients with BTC with IDH1 Mutations: A Retrospective Study
March 2023, Vol 4, No 1
Long-term outcomes were evaluated in patients with IDH1-mutated biliary tract cancer who were treated with systemic therapy.
Phase 2 Study of CTX-009 plus Paclitaxel in Patients with Advanced BTC
March 2023, Vol 4, No 1
CTX-009 plus paclitaxel showed promising efficacy as second- or third-line treatment in patients with advanced biliary tract cancer.
Gunagratinib in Patients with Previously Treated Advanced CCA Harboring FGFR2 Fusions or Rearrangements
March 2023, Vol 4, No 1
Gunagratinib showed promising efficacy as a second-generation FGFR inhibitor and demonstrated potential to treat multiple FGFR pathway abnormalities.
Results from SWOG 1815: GemCis and Nab-Paclitaxel versus GemCis in Advanced BTC
March 2023, Vol 4, No 1
The SWOG 1815 trial found that treatment with gemcitabine/cisplatin and paclitaxel (GAP) did not result in a significant improvement in survival compared with gemcitabine and cisplatin in patients with advanced biliary tract cancer, though GAP may be beneficial in patients with locally advanced disease and GBC.
JCOG1202 Subgroup Analysis: Risk Factors for Early Relapse in Patients Undergoing Curative Resection
March 2023, Vol 4, No 1
A study of patients with resected biliary tract cancer (BTC) found that postoperative CA 19-9 level, tumor differentiation, lymph node metastases, and residual tumor significantly impact early relapse in patients with curatively resected BTC. Similar risk factors were also found in patients receiving adjuvant S-1.
Impact of Gene Expression in 5-FU Metabolic Pathways on Outcomes in Patients Enrolled in JCOG1202
March 2023, Vol 4, No 1
Results from a study evaluating the impact of 5-FU metabolic pathway enzyme expression on outcomes of patients with curatively resected biliary tract cancer showed that relapse-free survival was improved in patients with certain enzymes who received adjuvant S-1.
Atezolizumab with or without Bevacizumab in Combination with GemCis in Advanced BTC: Results from IMbrave 151
March 2023, Vol 4, No 1
Researchers assessed whether VEGF blockade plus chemotherapy with gemcitabine/cisplatin can enhance responses to PD-L1 inhibition by promoting an immune-permissive tumor microenvironment in patients with advanced biliary tract cancer.
Nab-Paclitaxel plus Sintilimab as Second-Line Treatment for Advanced BTC
March 2023, Vol 4, No 1
The safety and efficacy of second-line nab-paclitaxel combined with the anti-PD-1 antibody sintilimab was studied in patients with advanced biliary tract cancer.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: